231 related articles for article (PubMed ID: 27185866)
1. Long-term glucocorticoid effect on bone mineral density in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
Ceccato F; Barbot M; Albiger N; Zilio M; De Toni P; Luisetto G; Zaninotto M; Greggio NA; Boscaro M; Scaroni C; Camozzi V
Eur J Endocrinol; 2016 Aug; 175(2):101-6. PubMed ID: 27185866
[TBL] [Abstract][Full Text] [Related]
2. Bone mineral density is not significantly reduced in adult patients on low-dose glucocorticoid replacement therapy.
Koetz KR; Ventz M; Diederich S; Quinkler M
J Clin Endocrinol Metab; 2012 Jan; 97(1):85-92. PubMed ID: 21994966
[TBL] [Abstract][Full Text] [Related]
3. Bone Mass in Young Patients with Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency.
Espinosa Reyes TM; Leyva González G; Domínguez Alonso E; Falhammar H
Horm Res Paediatr; 2021; 94(1-2):1-8. PubMed ID: 34044395
[TBL] [Abstract][Full Text] [Related]
4. Bone mineral density, bone markers, and fractures in adult males with congenital adrenal hyperplasia.
Falhammar H; Filipsson Nyström H; Wedell A; Brismar K; Thorén M
Eur J Endocrinol; 2013 Mar; 168(3):331-41. PubMed ID: 23211577
[TBL] [Abstract][Full Text] [Related]
5. Bone mineral density in relation to glucocorticoid substitution therapy in adult patients with 21-hydroxylase deficiency.
Jääskeläinen J; Voutilainen R
Clin Endocrinol (Oxf); 1996 Dec; 45(6):707-13. PubMed ID: 9039336
[TBL] [Abstract][Full Text] [Related]
6. Dual energy X-ray absorptiometry outcomes in male COPD patients after treatment with different glucocorticoid regimens.
Dubois EF; Röder E; Dekhuijzen PN; Zwinderman AE; Schweitzer DH
Chest; 2002 May; 121(5):1456-63. PubMed ID: 12006428
[TBL] [Abstract][Full Text] [Related]
7. Therapy of moderate-to-severe Graves' orbitopathy with intravenous methylprednisolone pulses is not associated with loss of bone mineral density.
Rymuza J; Popow M; Żurecka Z; Przedlacki J; Bednarczuk T; Miśkiewicz P
Endocrine; 2019 May; 64(2):308-315. PubMed ID: 30506426
[TBL] [Abstract][Full Text] [Related]
8. Association of androgen excess and bone mineral density in women with classical congenital adrenal hyperplasia with 21-hydroxylase deficiency.
Lee DH; Kong SH; Jang HN; Ahn CH; Lim SG; Lee YA; Kim SW; Kim JH
Arch Osteoporos; 2022 Mar; 17(1):45. PubMed ID: 35258698
[TBL] [Abstract][Full Text] [Related]
9. Bone mineral density in girls with classical congenital adrenal hyperplasia due to CYP21 deficiency.
Elnecave RH; Kopacek C; Rigatto M; Keller Brenner J; Sisson de Castro JA
J Pediatr Endocrinol Metab; 2008 Dec; 21(12):1155-62. PubMed ID: 19189689
[TBL] [Abstract][Full Text] [Related]
10. Normal bone health in young adults with 21-hydroxylase enzyme deficiency undergoing glucocorticoid replacement therapy.
Borges JH; de Oliveira DM; de Lemos-Marini SHV; Geloneze B; Guerra-Júnior G; Gonçalves EM
Osteoporos Int; 2022 Jan; 33(1):283-291. PubMed ID: 34406442
[TBL] [Abstract][Full Text] [Related]
11. Fractures and bone mineral density in adult women with 21-hydroxylase deficiency.
Falhammar H; Filipsson H; Holmdahl G; Janson PO; Nordenskjöld A; Hagenfeldt K; Thorén M
J Clin Endocrinol Metab; 2007 Dec; 92(12):4643-9. PubMed ID: 17878254
[TBL] [Abstract][Full Text] [Related]
12. Bone mineral density and bone turnover in Romanian children and young adults with classical 21-hydroxylase deficiency are influenced by glucocorticoid replacement therapy.
Zimmermann A; Sido PG; Schulze E; Al Khzouz C; Lazea C; Coldea C; Weber MM
Clin Endocrinol (Oxf); 2009 Oct; 71(4):477-84. PubMed ID: 19170706
[TBL] [Abstract][Full Text] [Related]
13. Impact of total cumulative glucocorticoid dose on bone mineral density in patients with 21-hydroxylase deficiency.
Chakhtoura Z; Bachelot A; Samara-Boustani D; Ruiz JC; Donadille B; Dulon J; Christin-Maître S; Bouvattier C; Raux-Demay MC; Bouchard P; Carel JC; Leger J; Kuttenn F; Polak M; Touraine P;
Eur J Endocrinol; 2008 Jun; 158(6):879-87. PubMed ID: 18390993
[TBL] [Abstract][Full Text] [Related]
14. Correlation of Bone Mineral Parameters with Anthropometric Measurements and the Effect of Glucocorticoids on Bone Mineral Parameters in Congenital Adrenal Hyperplasia.
Ganesh R; Suresh N; Janakiraman L; Ravikumar K
Indian J Pediatr; 2016 Feb; 83(2):126-30. PubMed ID: 26223873
[TBL] [Abstract][Full Text] [Related]
15. The threshold of bone mineral density for vertebral fracture in female patients with glucocorticoid-induced osteoporosis.
Kaji H; Yamauchi M; Chihara K; Sugimoto T
Endocr J; 2006 Feb; 53(1):27-34. PubMed ID: 16543669
[TBL] [Abstract][Full Text] [Related]
16. Bone mineral density and body composition in prepubertal and adolescent patients with the classical form of 21-hydroxylase deficiency.
Sahakitrungruang T; Wacharasindhu S; Supornsilchai V; Srivuthana S; Kingpetch K
J Med Assoc Thai; 2008 May; 91(5):705-10. PubMed ID: 18672636
[TBL] [Abstract][Full Text] [Related]
17. Increased serum osteoprotegerin in patients with primary adrenal insufficiency receiving conventional hydrocortisone substitution.
Fichna M; Zurawek M; Fichna P; Gryczynska M; Nowak J; Ruchala M
J Physiol Pharmacol; 2012 Dec; 63(6):677-82. PubMed ID: 23388484
[TBL] [Abstract][Full Text] [Related]
18. Reduced bone mineral density and increased bone metabolism rate in young adult patients with 21-hydroxylase deficiency.
Sciannamblo M; Russo G; Cuccato D; Chiumello G; Mora S
J Clin Endocrinol Metab; 2006 Nov; 91(11):4453-8. PubMed ID: 16926248
[TBL] [Abstract][Full Text] [Related]
19. Bone mineral density and fractures in congenital adrenal hyperplasia: Findings from the dsd-LIFE study.
Riehl G; Reisch N; Roehle R; Claahsen van der Grinten H; Falhammar H; Quinkler M
Clin Endocrinol (Oxf); 2020 Apr; 92(4):284-294. PubMed ID: 31886890
[TBL] [Abstract][Full Text] [Related]
20. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy.
Van Staa TP; Laan RF; Barton IP; Cohen S; Reid DM; Cooper C
Arthritis Rheum; 2003 Nov; 48(11):3224-9. PubMed ID: 14613287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
